Corvidia is now part of Novo Nordisk. Visit https://www.novonordisk-us.com/ to learn more.
Total raised: $86M
Investors 4
| Date | Name | Website |
| - | Apple Tree... | appletreep... |
| - | Sofinnova ... | sofinnovap... |
| - | BioHealth ... | biohealthi... |
| - | Andera Par... | anderapart... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 25.04.2018 | Series B | $60M | - |
| 17.02.2016 | Series A | $26M | Apple Tree... |
Mentions in press and media 11
| Date | Title | Description |
| 13.06.2024 | The Lustgarten Foundation Appoints Two New Board Members | To date, the foundation has invested more than $282M in high-risk, high-reward research to accelerate and expand life-saving treatment options. Richard Barakat, MD, and Aaron Kantoff join the Lustgarten Foundation Board of Directors WOODBUR... |
| 08.01.2021 | Venrock’s Bryan Roberts on the firm’s new $450 million fund, and where it’s shopping in 2021 | Venrock, the 51-year-old firm that started as the venture arm of the Rockefeller family, has closed its ninth fund with $450 million, the same amount it raised for its last two funds. The outfit, with offices in Palo Alto, New York and Camb... |
| 12.06.2020 | Novo Nordisk To Buy Corvidia Therapeutics For Up To $2.1B | 23 Shares Email Facebook Twitter LinkedIn Danish pharmaceutical company Novo Nordisk is buying Massachusetts-based biotech company Corvidia Therapeutics, the companies announced this week. Subscribe to the Crunchbase Daily The sale could ri... |
| 25.04.2018 | Corvidia Therapeutics Secures $60 Million in Series B Funding to Accelerate Clinical Work | Lead investor Venrock joined by Andera, Cormorant, HBM Healthcare Investments, Fresenius Medical Care Ventures GmbH, Sofinnova Partners, Apple Tree Partners and MedImmune Corvidia nears completion of its Phase 2 genetically-defined clinical... |
| 25.04.2018 | Corvidia Therapeutics Secures $60 Million in Series B Funding | |
| 25.04.2018 | Corvidia Therapeutics Raises $60 Million in Series B | WALTHAM, Mass.--(BUSINESS WIRE)--Corvidia Therapeutics Inc., a leading clinical stage biotechnology company, today announced the close of a $60 million USD Series B funding round. The financing will accelerate growth of Corvidia’s ongoing c... |
| 25.04.2018 | Venrock-backed startup Corvidia snags $60M round to develop ex-AstraZeneca drug | A new startup founded by a handful of ex-AstraZeneca folks has hauled in a $60 million Series B round led by Venrock to push forward its Phase II trial for advanced kidney disease. Michael Davidson The company was co-founded... |
| 25.04.2018 | Corvidia Therapeutics Secures $60M in Series B Funding | Corvidia Therapeutics Inc., a Waltham, Mass.-based clinical stage biotechnology company, closed a $60m Series B funding round. The round was led by Venrock with participation from Andera (formerly Edmond de Rothschild), Cormorant Asset Mana... |
| 18.02.2016 | Corvidia Therapeutics Raises $26M in a Series A | BOSTON, MA, Biotechnology company focused on the development of precision cardiovascular therapies, announced today that it has raised $26 million in a Series A financing. >> Click here for more funding data on Corvidia Therapeutic... |
| 17.02.2016 | Corvidia Therapeutics Raises $26M in a Series A Financing, Led by Sofinnova Partners and Apple Tree Partners | Corvidia Therapeutics, a biotechnology company focused on the development of precision cardiovascular therapies, announced today that it has raised $26 million in a Series A financing, co-led by seed-investor Sofinnova Partners, and Apple T... |
Show more